Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Augmented Betamethasone Dipropionate
2. Beloderm
3. Betamethasone Propionate
4. Betamethasone-17,21-dipropionate
5. Diprolene
6. Diprosone
7. Maxivate
1. Diprolene
2. Diprosone
3. 5593-20-4
4. Maxivate
5. Diprolene Af
6. Alphatrex
7. Diproderm
8. Psorion
9. Betamethasone 17,21-dipropionate
10. Rinderon Dp
11. Diprosis
12. Diprospan
13. Sch 11460
14. Sch-11460
15. S-3440
16. Betamethasone (as Dipropionate)
17. Betamethasone-17,21-dipropionate
18. Chebi:31276
19. Nsc-758415
20. Pregna-1,4-diene-3,20-dione,9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11b,16b)-
21. Beta-methasone 17,21-dipropionate
22. 826y60901u
23. [2-[(8s,9r,10s,11s,13s,14s,16s,17r)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] Propanoate
24. (11-beta,16-beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
25. 9-fluoro-11beta-hydroxy-16beta-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl Dipropanoate
26. 9-fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
27. 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione-17,21-dipropionate
28. Einecs 227-005-2
29. Brn 3638108
30. .beta.-methasone 17,21-dipropionate
31. Betamethasone Dipropionate (diprolene)
32. S 3440
33. Diprolene (tn)
34. Unii-826y60901u
35. Ncgc00159360-02
36. Ncgc00159443-02
37. Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11.beta.,16.beta.)-
38. Sernivo (tn)
39. Rinderon-dp (tn)
40. Betamethasone Dipropionate [usan:usp:jan]
41. Betamethasone-dipropionate
42. Dsstox_cid_2672
43. Betamethasone Diprop
44. Schembl7519
45. 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
46. Dsstox_rid_76683
47. Dsstox_gsid_22672
48. 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-di(propionate)
49. Betamethasone-17,21-dipropionate 100 Microg/ml In Acetonitrile
50. Chembl1200384
51. Dtxsid2022672
52. Component Of Betasone (salt/mix)
53. Component Of Alphatrex (salt/mix)
54. Amy22130
55. Zinc4212137
56. Tox21_113343
57. Bdbm50421892
58. S1688
59. Akos015969733
60. Betamethasone Dipropionate (jp17/usp)
61. Ccg-269732
62. Cs-7549
63. Ks-5303
64. Nsc 758415
65. Betamethasone Dipropionate [jan]
66. Betamethasone Dipropionate [usan]
67. Ncgc00159443-01
68. Ncgc00159443-05
69. (11beta,16beta)-9-fluoro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl Dipropanoate
70. 2-((2s,10s,11s,13s,15s,17s,1r,14r)-1-fluoro-17-hydroxy-2,13,15-trimethyl-5-oxo -14-propanoyloxytetracyclo[8.7.0.0<2,7>.0<11,15>]heptadeca-3,6-dien-14-yl)-2-o Xoethyl Propanoate
71. Betamethasone Dipropionate [mart.]
72. Betamethasone Dipropionate [vandf]
73. Hy-13571
74. Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methyl-, 17,21-dipropionate
75. Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11beta,16beta)
76. Betamethasone Dipropionate [usp-rs]
77. Betamethasone Dipropionate [who-dd]
78. Cas-5593-20-4
79. Betamethasone Dipropionate, Augmented
80. B3166
81. Betamethasone 17,21-dipropionate [mi]
82. Betamethasone Dipropionate [green Book]
83. Betamethasone Dipropionate [orange Book]
84. D01637
85. Ab01274713-01
86. Ab01274713_02
87. Betamethasone 17.alpha.,21-dipropionate
88. Betamethasone Dipropionate [ep Monograph]
89. Betamethasone Dipropionate [usp Monograph]
90. Wynzora Component Betamethasone Dipropionate
91. Enstilar Component Betamethasone Dipropionate
92. Lotrisone Component Betamethasone Dipropionate
93. Q4897349
94. Taclonex Component Betamethasone Dipropionate
95. Betamethasone Dipropionate Component Of Enstilar
96. Betamethasone Dipropionate Component Of Taclonex
97. Betamethasone Dipropionate Component Of Wynzora
98. Brd-k58148589-001-03-6
99. Leo-90100 Component Betamethasone Dipropionate
100. Betamethasone Dipropionate Component Of Lotrisone
101. Betamethasone Dipropionate Component Of Leo-90100
102. Betamethasone-17,21-dipropionate 100 Microg/ml In Methanol
103. (11.beta.,16.beta.)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
104. 9-fluoro-11.beta.-hydroxy-16.beta.-methyl-3,20-dioxo-17-(propionyloxy)pregna-1,4-dien-21-yl Propionate #
105. 9alpha-fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-1,4-pregnadiene-3,20-dione 17,21-dipropionate
106. 9alpha-fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-3,20-dioxopregna-1,4-diene- 17,21-diyl Dipropionate
107. Pregna-1,4-diene-3,20-dione, 9-fluoro-11-.beta.,17,21-trihydroxy-16-.beta.-methyl-,17,21-dipropionate
108. Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11.beta.,16.beta.)
| Molecular Weight | 504.6 g/mol |
|---|---|
| Molecular Formula | C28H37FO7 |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 8 |
| Exact Mass | 504.25233168 g/mol |
| Monoisotopic Mass | 504.25233168 g/mol |
| Topological Polar Surface Area | 107 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 1050 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 6 | |
|---|---|
| Drug Name | Betamethasone dipropionate |
| PubMed Health | Betamethasone Dipropionate (On the skin) |
| Drug Classes | Corticosteroid, Strong |
| Drug Label | Betamethasone Dipropionate Lotion USP 0.05% (Augmented) contains betamethasone dipropionate, USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a sli... |
| Active Ingredient | Betamethasone dipropionate |
| Dosage Form | Lotion; Ointment, augmented; Ointment; Lotion, augmented; Cream; Cream, augmented; Gel, augmented |
| Route | Topical |
| Strength | eq 0.05% base |
| Market Status | Prescription |
| Company | Glenmark Generics; Fougera Pharms; Actavis Mid Atlantic; Teva; Perrigo New York; Taro; Fougera; Tolmar |
| 2 of 6 | |
|---|---|
| Drug Name | Diprolene |
| PubMed Health | Betamethasone Dipropionate, Augmented (On the skin) |
| Drug Classes | Corticosteroid, Very Strong |
| Drug Label | DIPROLENE (augmented betamethasone dipropionate) Ointment contains betamethasone dipropionate USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a... |
| Active Ingredient | Betamethasone dipropionate |
| Dosage Form | Ointment, augmented; Lotion, augmented |
| Route | Topical |
| Strength | eq 0.05% base |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 3 of 6 | |
|---|---|
| Drug Name | Diprolene af |
| PubMed Health | Betamethasone Dipropionate, Augmented (On the skin) |
| Drug Classes | Corticosteroid, Very Strong |
| Drug Label | DIPROLENE AF Cream 0.05% contains betamethasone dipropionate USP, a synthetic adrenocorticosteroid, for dermatologic use in an emollient base. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a slight degre... |
| Active Ingredient | Betamethasone dipropionate |
| Dosage Form | Cream, augmented |
| Route | Topical |
| Strength | eq 0.05% base |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 4 of 6 | |
|---|---|
| Drug Name | Betamethasone dipropionate |
| PubMed Health | Betamethasone Dipropionate (On the skin) |
| Drug Classes | Corticosteroid, Strong |
| Drug Label | Betamethasone Dipropionate Lotion USP 0.05% (Augmented) contains betamethasone dipropionate, USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a sli... |
| Active Ingredient | Betamethasone dipropionate |
| Dosage Form | Lotion; Ointment, augmented; Ointment; Lotion, augmented; Cream; Cream, augmented; Gel, augmented |
| Route | Topical |
| Strength | eq 0.05% base |
| Market Status | Prescription |
| Company | Glenmark Generics; Fougera Pharms; Actavis Mid Atlantic; Teva; Perrigo New York; Taro; Fougera; Tolmar |
| 5 of 6 | |
|---|---|
| Drug Name | Diprolene |
| PubMed Health | Betamethasone Dipropionate, Augmented (On the skin) |
| Drug Classes | Corticosteroid, Very Strong |
| Drug Label | DIPROLENE (augmented betamethasone dipropionate) Ointment contains betamethasone dipropionate USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a... |
| Active Ingredient | Betamethasone dipropionate |
| Dosage Form | Ointment, augmented; Lotion, augmented |
| Route | Topical |
| Strength | eq 0.05% base |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 6 of 6 | |
|---|---|
| Drug Name | Diprolene af |
| PubMed Health | Betamethasone Dipropionate, Augmented (On the skin) |
| Drug Classes | Corticosteroid, Very Strong |
| Drug Label | DIPROLENE AF Cream 0.05% contains betamethasone dipropionate USP, a synthetic adrenocorticosteroid, for dermatologic use in an emollient base. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a slight degre... |
| Active Ingredient | Betamethasone dipropionate |
| Dosage Form | Cream, augmented |
| Route | Topical |
| Strength | eq 0.05% base |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - OINTMENT, AUGMENTED;TOPICAL - EQ 0.0...DOSAGE - OINTMENT, AUGMENTED;TOPICAL - EQ 0.05% BASE
USFDA APPLICATION NUMBER - 18741
DOSAGE - CREAM;TOPICAL - EQ 0.05% BASE;1% **F...DOSAGE - CREAM;TOPICAL - EQ 0.05% BASE;1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 18827
DOSAGE - CREAM;TOPICAL - EQ 0.05% BASE
USFDA APPLICATION NUMBER - 19137
DOSAGE - OINTMENT;TOPICAL - EQ 0.05% BASE
USFDA APPLICATION NUMBER - 19141
DOSAGE - CREAM, AUGMENTED;TOPICAL - EQ 0.05% ...DOSAGE - CREAM, AUGMENTED;TOPICAL - EQ 0.05% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 19555
DOSAGE - LOTION, AUGMENTED;TOPICAL - EQ 0.05%...DOSAGE - LOTION, AUGMENTED;TOPICAL - EQ 0.05% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 19716
DOSAGE - OINTMENT;TOPICAL - 0.064%;0.005%
USFDA APPLICATION NUMBER - 21852
DOSAGE - SUSPENSION;TOPICAL - 0.064%;0.005%
USFDA APPLICATION NUMBER - 22185
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lubrizol Life Science Health
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shandong Focus Biotechnology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Film Formers & Plasticizers
Emulsifying Agents
Solubilizers
Parenteral
Thickeners and Stabilizers
Coating Systems & Additives
Lubricants & Glidants
Fillers, Diluents & Binders
Taste Masking
Controlled & Modified Release
Direct Compression
Surfactant & Foaming Agents
Granulation
Chewable & Orodispersible Aids
Soft Gelatin
Rheology Modifiers
Co-Processed Excipients
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
14
PharmaCompass offers a list of Betamethasone Dipropionate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Betamethasone Dipropionate manufacturer or Betamethasone Dipropionate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Betamethasone Dipropionate manufacturer or Betamethasone Dipropionate supplier.
PharmaCompass also assists you with knowing the Betamethasone Dipropionate API Price utilized in the formulation of products. Betamethasone Dipropionate API Price is not always fixed or binding as the Betamethasone Dipropionate Price is obtained through a variety of data sources. The Betamethasone Dipropionate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Maxivate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Maxivate, including repackagers and relabelers. The FDA regulates Maxivate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Maxivate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Maxivate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Maxivate supplier is an individual or a company that provides Maxivate active pharmaceutical ingredient (API) or Maxivate finished formulations upon request. The Maxivate suppliers may include Maxivate API manufacturers, exporters, distributors and traders.
click here to find a list of Maxivate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Maxivate DMF (Drug Master File) is a document detailing the whole manufacturing process of Maxivate active pharmaceutical ingredient (API) in detail. Different forms of Maxivate DMFs exist exist since differing nations have different regulations, such as Maxivate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Maxivate DMF submitted to regulatory agencies in the US is known as a USDMF. Maxivate USDMF includes data on Maxivate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Maxivate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Maxivate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Maxivate Drug Master File in Japan (Maxivate JDMF) empowers Maxivate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Maxivate JDMF during the approval evaluation for pharmaceutical products. At the time of Maxivate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Maxivate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Maxivate Drug Master File in Korea (Maxivate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Maxivate. The MFDS reviews the Maxivate KDMF as part of the drug registration process and uses the information provided in the Maxivate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Maxivate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Maxivate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Maxivate suppliers with KDMF on PharmaCompass.
A Maxivate CEP of the European Pharmacopoeia monograph is often referred to as a Maxivate Certificate of Suitability (COS). The purpose of a Maxivate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Maxivate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Maxivate to their clients by showing that a Maxivate CEP has been issued for it. The manufacturer submits a Maxivate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Maxivate CEP holder for the record. Additionally, the data presented in the Maxivate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Maxivate DMF.
A Maxivate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Maxivate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Maxivate suppliers with CEP (COS) on PharmaCompass.
A Maxivate written confirmation (Maxivate WC) is an official document issued by a regulatory agency to a Maxivate manufacturer, verifying that the manufacturing facility of a Maxivate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Maxivate APIs or Maxivate finished pharmaceutical products to another nation, regulatory agencies frequently require a Maxivate WC (written confirmation) as part of the regulatory process.
click here to find a list of Maxivate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Maxivate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Maxivate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Maxivate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Maxivate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Maxivate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Maxivate suppliers with NDC on PharmaCompass.
Maxivate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Maxivate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Maxivate GMP manufacturer or Maxivate GMP API supplier for your needs.
A Maxivate CoA (Certificate of Analysis) is a formal document that attests to Maxivate's compliance with Maxivate specifications and serves as a tool for batch-level quality control.
Maxivate CoA mostly includes findings from lab analyses of a specific batch. For each Maxivate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Maxivate may be tested according to a variety of international standards, such as European Pharmacopoeia (Maxivate EP), Maxivate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Maxivate USP).
